Senior Director Regulatory Affairs CMC
Richard Dennett heads Regulatory Affairs CMC activities at PPD and provides expertise, technical guidance and leadership for global CMC regulatory strategy.
He additionally chairs PPD’s Advanced Therapy Forum ; a cross departmental platform’ which connects across all relevant CRO functions.
Richard has worked on several MAA/BLA submissions though to successful EMA/FDA approval.
Richard joined PPD in 2017 having previously held strategic product development roles including global Regulatory & Technical CMC strategy, cGMP compliance, hands on ‘start to finish’ lead product development though to commercial/regulatory market approval for a complex biopharmaceutical, contract development manufacture across multiple product classes.
He has previously held wide-ranging strategic positions at AstraZeneca and Celltech-Medeva (Novartis) and, in addition, was company co-founder of Eden Biodesign (Allergan) which realised and commercially operated the former UK National Biomanufacturing Centre as a successful CMO.
Richard obtained his degree and PhD in Biochemistry at Liverpool, UK
Wednesday, September 16, 2020
12:05 PM – 1:00 PM EDT